<i>FLT3</i> mutations in acute myeloid leukemia: a review focusing on clinically applicable drugs
Jae-Sook Ahn, Hyeoung‐Joon Kim
Abstract
FMS-like tyrosine kinase 3 (FLT3) mutations, the most frequently detected genetic aberrations in patients with acute myeloid leukemia (AML), are identified in approximately 30% of patients with newly diagnosed AML and are more common in patients with normal karyotypes. Since the discovery of FLT3 mutations in AML, clinical trials have been actively conducted in patients with FLT3 mutated AML, and FLT3 inhibitors have been introduced into clinical practice. The current standard treatment for patients with newly diagnosed FLT3-mutated AML is 7+3 induction chemotherapy combined with midostaurin.
Topics & Concepts
MedicineMyeloid leukemiaMyeloidLeukemiaOncologyBioinformaticsIntensive care medicinePharmacologyInternal medicineBiologyAcute Myeloid Leukemia ResearchChronic Myeloid Leukemia TreatmentsAcute Lymphoblastic Leukemia research